AVTR Stock Recent News

RADNOR, Pa. , June 27, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, announced that it will release its second quarter 2025 financial results before the market opens on Friday, August 1, and will hold a conference call on the same day at 8:00 a.m.

Avantor is trading at its lowest valuation since 2019, attracting significant management buying of the stock, with clear chart accumulation trends since April. AVTR has been aggressively repaying debt, selling assets and restructuring operations, aiming for $400-500 million in annual savings by late 2026, especially if sales rebound. Risks include potential trade tariffs, U.S. healthcare research spending cuts, and recession, but insider votes of confidence (share buying) suggest a bullish outlook for new investment.

RADNOR, Pa. , May 16, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, announced that Brent Jones, Executive Vice President and Chief Financial Officer, will be participating in a fireside chat at the RBC Capital Markets Global Healthcare Conference in New York on Tuesday, May 20, 2025 at approximately 8:00 a.m.

RADNOR, Pa. , May 2, 2025 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, announced that Michael Stubblefield, President and CEO, will be participating in a fireside chat at the Bank of America Securities 2025 Health Care Conference in Las Vegas on Tuesday, May 13, 2025 at approximately 10:00 a.m.

AVTR's Bioscience Production segment witnesses robust growth amid macroeconomic pressures.

Avantor Inc AVTR reported in-line earnings for its first quarter on Friday.

Avantor's shares have nearly halved since October, driven by lackluster organic growth, elevated debt, and a mixed financial track record. The company operates in two segments, generating nearly $7 billion in sales, with significant exposure to laboratory solutions and bioscience production. Despite a reduction in net debt and lower earnings multiples, the business faces ongoing challenges, including flat organic growth and a high leverage ratio.

Avantor Inc AVTR on Friday reported adjusted EPS of 23 cents in line with consensus.

Avantor (AVTR) shares sank 16% Friday after the maker of lab chemicals and other life sciences products announced its CEO was resigning, reported weaker-than-expected net sales as government spending fell, and slashed its guidance.

Avantor, Inc. (NYSE:AVTR ) Q1 2025 Earnings Call April 25, 2025 8:00 AM ET Company Participants Allison Hosak - SVP of Global Communications and Brand Michael Stubblefield - President and CEO R. Brent Jones - EVP and CFO Conference Call Participants Michael Ryskin - Bank of America Securities Vijay Kumar - Evercore ISI Rachel Vatnsdal - J.P.